ViaCyte is developing a drug delivery system, Encaptra™, that is retrievable, non-biodegradable, vascularizing and that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells. The Encaptra™ drug delivery system is manufactured from FDA compliant implant grade materials and is being designed with the goal of eliminating the need for continuous immunosuppressant drugs.  The Encaptra™ drug delivery system is optimized for release of insulin in response to the recipient’s blood glucose and designed for subcutaneous implantation providing complete containment of the product cells with full retrieval capability.